+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
ID06212193

Early Feasibility Study to Evaluate Safety and Performance of Innoventric Trillium Stent Graft for Severe Tricuspid Regurgitation Treatment

Led by Innoventric LTD · Updated on 2026-11-04

25

Participants Needed

10

Research Sites

258 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and performance of the Innoventric Trillium Stent Graft in treating patients with severe or greater tricuspid regurgitation TR. This early feasibility study involves up to 15 patients across investigational sites in the US and Germany. The study focuses on patients who have significant TR and are not suitable for or have refused standard surgical or interventional therapies. Participants will undergo a transcatheter cross-caval tricuspid valve replacement using the Innoventric Trillium Stent Graft. This device-based treatment is delivered during a single procedure. Following the procedure, patients will be monitored at discharge and at multiple follow-up points including 1 month, 3 months, 6 months, and yearly up to 5 years to assess the devices safety and technical performance. During the study, patients will have assessments at baseline, during the procedure, and at scheduled follow-ups. These evaluations include monitoring for major adverse events shortly after the procedure and over several years, as well as checking the devices efficacy. The total participation duration can extend up to 5 years, with visits designed to track safety, performance, and patient outcomes over time.

CONDITIONS

Brief Title

Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)

Research Team

C

Chen Lereya

A

Amir Danino

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here